Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 6/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594932 | 0.83 | MAPT (0.50) | MGLLKDM4EMAPT | |
| SCHEMBL20529712 | 0.77 | MAPT (0.44) | HDAC1KDM4EMAPTNPSR1 | |
| SCHEMBL18638566 | 0.76 | HDAC2 (0.50) | HDAC2HDAC1HDAC3KIF11GSK3B | |
| SCHEMBL4899337 | 0.75 | HDAC2 (0.42) | HDAC2HDAC1KCNQ2KCNQ3KCNQ4 | |
| SCHEMBL2309636 | 0.74 | TOP2A (0.43) | KDM4EMAPT | |
| SCHEMBL2313211 | 0.74 | PTGER4 (0.47) | HDAC1KDM4EMAPT | |
| SCHEMBL28450779 | 0.73 | TOP2A (0.53) | HDAC2HDAC1HDAC3KDM4EMAPT | |
| SCHEMBL8609704 | 0.73 | MAPT (0.62) | KDM4EMAPT | |
| SCHEMBL26665186 | 0.72 | MAPT (0.53) | HDAC2HDAC1HDAC3KCNQ2KCNQ3 | |
| SCHEMBL14955457 | 0.72 | TRPV4 (0.55) | MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | HDAC2 1216/4885HDAC1 201/4885HDAC3 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.